Abbott Laboratories (NYSE:ABT) Given New $142.00 Price Target at Barclays

Abbott Laboratories (NYSE:ABT) had its price target cut by Barclays from $169.00 to $142.00 in a research report released on Monday, Marketbeat reports. They currently have an overweight rating on the healthcare product maker’s stock.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Citigroup lowered their target price on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Jefferies Financial Group upped their price target on Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Finally, Wells Fargo & Company upped their target price on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Trading Up 0.2%

Shares of NYSE:ABT opened at $109.51 on Monday. The company has a market capitalization of $190.43 billion, a PE ratio of 29.44, a P/E/G ratio of 1.74 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23. The business’s fifty day simple moving average is $122.41 and its 200-day simple moving average is $127.35.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the prior year, the business posted $1.34 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date is Thursday, January 15th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Abbott Laboratories by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after acquiring an additional 2,402,408 shares during the last quarter. State Street Corp lifted its position in Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after purchasing an additional 689,517 shares during the period. Capital International Investors boosted its holdings in Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after purchasing an additional 1,478,076 shares during the last quarter. Geode Capital Management LLC grew its position in Abbott Laboratories by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after purchasing an additional 1,390,554 shares during the period. Finally, Norges Bank purchased a new position in shares of Abbott Laboratories during the 2nd quarter valued at about $3,026,180,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s CEO personally invested roughly $2M while the stock has been under pressure — a management buy that signals confidence to shareholders and can help stabilize sentiment. Article Title
• Positive Sentiment: Freedom Capital upgraded ABT to a Buy (recently lowering its PT to $120), which gives the stock a retail/institutional buying narrative despite the lower target. Article Title
• Positive Sentiment: Long‑term bull case pieces note Abbott’s Dividend Aristocrat status, multi‑year revenue growth and strong balance sheet, reinforcing a buy-and-hold thesis for income/quality investors. Article Title
• Positive Sentiment: Opinion/bull-case coverage outlines structural upside from diagnostics and recurring revenue streams, offering a narrative that could attract growth‑oriented buyers. Article Title
• Neutral Sentiment: Abbott’s deal with Exact Sciences is reshaping its diagnostics footprint (strategic upside), but its nutrition business is undergoing a reset — a mixed development that likely means longer lead times before clear earnings upside. Article Title
• Neutral Sentiment: Barclays trimmed its price target from $169 to $142 but kept an Overweight rating, signaling conviction in Abbott’s story despite near-term headwinds. Article Title
• Neutral Sentiment: Valuation comparisons (e.g., Zacks piece on NVST vs ABT) highlight Abbott as a relatively lower-volatility, dividend-oriented option — useful context but not an immediate catalyst. Article Title
• Negative Sentiment: Daiwa cut its price target to $113 — a downgrade that adds selling pressure from analysts and may weigh on near‑term sentiment. Article Title
• Negative Sentiment: Leerink lowered its target to $119, another analyst haircut that contributes to a chorus of reduced near‑term expectations. Article Title

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.